These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 14557631

  • 1. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.
    Fikkert V, Van Maele B, Vercammen J, Hantson A, Van Remoortel B, Michiels M, Gurnari C, Pannecouque C, De Maeyer M, Engelborghs Y, De Clercq E, Debyser Z, Witvrouw M.
    J Virol; 2003 Nov; 77(21):11459-70. PubMed ID: 14557631
    [Abstract] [Full Text] [Related]

  • 2. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.
    Fikkert V, Hombrouck A, Van Remoortel B, De Maeyer M, Pannecouque C, De Clercq E, Debyser Z, Witvrouw M.
    AIDS; 2004 Oct 21; 18(15):2019-28. PubMed ID: 15577623
    [Abstract] [Full Text] [Related]

  • 3. Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
    Hombrouck A, Voet A, Van Remoortel B, Desadeleer C, De Maeyer M, Debyser Z, Witvrouw M.
    Antimicrob Agents Chemother; 2008 Jun 21; 52(6):2069-78. PubMed ID: 18378713
    [Abstract] [Full Text] [Related]

  • 4. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.
    Lee DJ, Robinson WE.
    J Virol; 2004 Jun 21; 78(11):5835-47. PubMed ID: 15140981
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance.
    Zahm JA, Bera S, Pandey KK, Vora A, Stillmock K, Hazuda D, Grandgenett DP.
    Antimicrob Agents Chemother; 2008 Sep 21; 52(9):3358-68. PubMed ID: 18591263
    [Abstract] [Full Text] [Related]

  • 6. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.
    Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD.
    Science; 2000 Jan 28; 287(5453):646-50. PubMed ID: 10649997
    [Abstract] [Full Text] [Related]

  • 7. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M, Ibanescu RI, Anstett K, Mésplède T, Routy JP, Robbins MA, Brenner BG, Montreal Primary HIV (PHI) Cohort Study Group.
    Retrovirology; 2018 Aug 17; 15(1):56. PubMed ID: 30119633
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J, Mesplède T, Oliveira M, Anstett K, Wainberg MA.
    J Virol; 2015 Nov 17; 89(22):11269-74. PubMed ID: 26311878
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
    Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A, Fujiwara T.
    Antimicrob Agents Chemother; 2008 Mar 17; 52(3):901-8. PubMed ID: 18160521
    [Abstract] [Full Text] [Related]

  • 13. Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors.
    King PJ, Lee DJ, Reinke RA, Victoria JG, Beale K, Robinson WE.
    Virology; 2003 Feb 01; 306(1):147-61. PubMed ID: 12620807
    [Abstract] [Full Text] [Related]

  • 14. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z, Kuritzkes DR.
    J Virol; 2014 Aug 01; 88(16):9268-76. PubMed ID: 24899199
    [Abstract] [Full Text] [Related]

  • 15. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
    Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T.
    Antimicrob Agents Chemother; 2011 Feb 01; 55(2):813-21. PubMed ID: 21115794
    [Abstract] [Full Text] [Related]

  • 16. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.
    AIDS Rev; 2009 Feb 01; 11(1):17-29. PubMed ID: 19290031
    [Abstract] [Full Text] [Related]

  • 17. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K, Fusco R, Cutillas V, Mesplède T, Wainberg MA.
    J Virol; 2015 Oct 01; 89(20):10482-8. PubMed ID: 26246578
    [Abstract] [Full Text] [Related]

  • 18. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I, Subra F, Charpentier C, Collin G, Descamps D, Calvez V, Marcelin AG, Delelis O.
    mBio; 2017 Sep 26; 8(5):. PubMed ID: 28951475
    [Abstract] [Full Text] [Related]

  • 19. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
    Mesplède T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA.
    J Antimicrob Chemother; 2014 Oct 26; 69(10):2733-40. PubMed ID: 24917583
    [Abstract] [Full Text] [Related]

  • 20. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
    Jones GS, Yu F, Zeynalzadegan A, Hesselgesser J, Chen X, Chen J, Jin H, Kim CU, Wright M, Geleziunas R, Tsiang M.
    Antimicrob Agents Chemother; 2009 Mar 26; 53(3):1194-203. PubMed ID: 19104010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.